Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
2.580
+0.290 (12.66%)
At close: Feb 5, 2026, 4:00 PM EST
2.599
+0.019 (0.74%)
After-hours: Feb 5, 2026, 7:59 PM EST
Opus Genetics Revenue
Opus Genetics had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -20.38%. This brings the company's revenue in the last twelve months to $14.63M, up 74.60% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$14.63M
Revenue Growth
+74.60%
P/S Ratio
8.76
Revenue / Employee
$812,944
Employees
18
Market Cap
177.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 75.00K | - | - |
| Dec 31, 2007 | 75.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 113.34M |
| Zentalis Pharmaceuticals | 26.87M |
| ProQR Therapeutics | 18.86M |
| Innate Pharma | 14.84M |
| Prelude Therapeutics | 10.50M |
| Compugen | 6.90M |
| Molecular Partners AG | 856.30K |
IRD News
- 3 days ago - Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 - GlobeNewsWire
- 9 days ago - Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa - GlobeNewsWire
- 21 days ago - Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - GlobeNewsWire
- 7 weeks ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - GlobeNewsWire
- 2 months ago - Opus Genetics to Participate in Upcoming Investment Conferences - GlobeNewsWire